{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T19:04:46Z","timestamp":1785438286246,"version":"3.56.0"},"reference-count":72,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T00:00:00Z","timestamp":1745884800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objective: Among the inflammatory bowel illnesses, ulcerative colitis (UC) affects 5 million people worldwide. UC manifests as weight loss, rectal bleeding, persistent diarrhea, and abdominal pain. Experimental research focused into the potential benefits of atorvastatin for colitis, although the literature only has a small amount of clinical evidence. To examine atorvastatin\u2019s protective effect in UC patients by assessing its impact on fecal myeloperoxidase, zonulin, and disease activity index (DAI). Methods: Two groups of patients with mild to moderate UC were randomly assigned. Over a six-month period, the control group (placebo group) received a placebo alongside mesalamine (1 g, three times daily [t.i.d.]). The atorvastatin group received atorvastatin (80 mg once daily) in addition to mesalamine (1 g t.i.d.). Disease severity was assessed by a gastroenterologist using the Disease Activity Index (DAI). Serum zonulin and fecal myeloperoxidase levels were measured before and after treatment to assess the biological efficacy of the interventions. Outcomes: Reduction in DAI and biomarker levels. Results: Both groups showed a significant decrease in DAI, zonulin, and fecal myeloperoxidase levels. However, the atorvastatin group (n = 23) demonstrated a significantly greater decrease in zonulin (p = 0.04), fecal myeloperoxidase (p = 0.03), and DAI (p = 0.001) compared to the placebo group (n = 24). In atorvastatin group, a significant correlation was observed between DAI and zonulin (p = 0.007, r = 0.4) and myeloperoxidase (p = 0.02, r = 0.36). Conclusions: The co-administration of atorvastatin may serve as a potential adjunct therapy for patients with UC.<\/jats:p>","DOI":"10.3390\/jcm14093077","type":"journal-article","created":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T07:49:36Z","timestamp":1745912976000},"page":"3077","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Repurposing Atorvastatin, HMGCO-A Reductase Inhibitor, in Patients with Ulcerative Colitis: A Randomized Controlled Study"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-6186-848X","authenticated-orcid":false,"given":"Hayam Ali","family":"AlRasheed","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice, College of Pharmacy, Princess Nourah bint Addulrahman University, Riyadh 84428, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahar M.","family":"El-Haggar","sequence":"additional","affiliation":[{"name":"Clinical Pharmacy Department, Faculty of Pharmacy, Tanta University, El-Guiesh Street, El-Gharbia Government, Tanta 31527, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahar K.","family":"Hegazy","sequence":"additional","affiliation":[{"name":"Clinical Pharmacy Department, Faculty of Pharmacy, Tanta University, El-Guiesh Street, El-Gharbia Government, Tanta 31527, Egypt"},{"name":"Pharmacy Practice Department, Faculty of Pharmacy, Horus University, New Damietta 7952567, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maha M.","family":"Maher","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Faculty of Medicine, Horus University, New Damietta 7952567, Egypt"},{"name":"Internal Medicine Department, Faculty of Medicine, Mansoura University, Mansoura 35516, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monir M.","family":"Bahgat","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Faculty of Medicine, Mansoura University, Mansoura 35516, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3332-4573","authenticated-orcid":false,"given":"Mostafa M.","family":"Bahaa","sequence":"additional","affiliation":[{"name":"Pharmacy Practice Department, Faculty of Pharmacy, Horus University, New Damietta 7952567, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,4,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1093\/ibd\/izae032","article-title":"Comparison of fecal calprotectin and myeloperoxidase in predicting outcomes in inflammatory bowel disease","volume":"31","author":"Swaminathan","year":"2025","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Madill-Thomsen, K.S., Venner, J.M., Parsons, D.E., Famulski, K.S., Thiesen, A.L., Hoque, S., Kroeker, K.I., Wong, K., Peerani, F., and Dieleman, L.A. (2025). Relating the molecular phenotype of ulcerative colitis to the clinical course. Sci. Rep., 15.","DOI":"10.1038\/s41598-025-90618-8"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.cgh.2018.08.001","article-title":"AGA clinical practice update on functional gastrointestinal symptoms in patients with inflammatory bowel disease: Expert review","volume":"17","author":"Colombel","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1146\/annurev-pathol-012615-044152","article-title":"Genetics and pathogenesis of inflammatory bowel disease","volume":"11","author":"Liu","year":"2016","journal-title":"Annu. Rev. Pathol. Mech. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1111\/apt.17988","article-title":"A practical approach to persistent gastrointestinal symptoms in inflammatory bowel disease in remission","volume":"59","author":"Aliu","year":"2024","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1089\/jmf.2023.K.0247","article-title":"Anthocyanin Extracted from Purple Sweet Potato Alleviates Dextran Sulfate Sodium-Induced Colitis in Mice by Suppressing Pyroptosis and Altering Intestinal Flora Structure","volume":"27","author":"Chen","year":"2024","journal-title":"J. Med. Food"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/s41575-023-00774-3","article-title":"The appendix and ulcerative colitis\u2014An unsolved connection","volume":"20","author":"Agrawal","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/s41577-024-01008-6","article-title":"Strategies for targeting cytokines in inflammatory bowel disease","volume":"24","author":"Neurath","year":"2024","journal-title":"Nat. Rev. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1093\/ibd\/izae054","article-title":"Continuous monitoring of CRP, IL-6, and calprotectin in inflammatory bowel disease using a perspiration-based wearable device","volume":"31","author":"Shahub","year":"2025","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_10","first-page":"1097","article-title":"Recent advances in epidemiology, pathogenesis, diagnosis, and treatment of inflammatory bowel disease: Insights from the past two years","volume":"10","author":"Wan","year":"2025","journal-title":"Chin. Med. J."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/S2468-1253(24)00355-8","article-title":"Overcoming the challenges of overtreating and undertreating inflammatory bowel disease","volume":"10","author":"Temido","year":"2025","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Hirten, R.P., Lin, K.-C., Whang, J., Shahub, S., Churcher, N.K., Helmus, D., Muthukumar, S., Sands, B., and Prasad, S. (2024). Longitudinal monitoring of IL-6 and CRP in inflammatory bowel disease using IBD-AWARE. Biosens. Bioelectron. X, 16.","DOI":"10.1016\/j.biosx.2023.100435"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Bahrami, S., Babaei, N., Esmaeili Gouvarchin Ghaleh, H., Mohajeri Borazjani, J., and Farzanehpour, M. (2024). Investigating the effects of combined treatment of mesalazine with Lactobacillus casei in the experimental model of ulcerative colitis. Front. Mol. Biosci., 11.","DOI":"10.3389\/fmolb.2024.1456053"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"G\u00f3recka, A., Jura-P\u00f3\u0142torak, A., Ko\u017ama, E.M., Szeremeta, A., Olczyk, K., and Komosi\u0144ska-Vassev, K. (2024). Biochemical modulators of tight junctions (TJs): Occludin, claudin-2 and zonulin as biomarkers of intestinal barrier leakage in the diagnosis and assessment of inflammatory bowel disease progression. Molecules, 29.","DOI":"10.3390\/molecules29194577"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Szymanska, E., Wierzbicka, A., Dadalski, M., and Kierkus, J. (2021). Fecal Zonulin as a noninvasive biomarker of intestinal permeability in pediatric patients with inflammatory bowel diseases\u2014Correlation with disease activity and fecal calprotectin. J. Clin. Med., 10.","DOI":"10.3390\/jcm10173905"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2472754","DOI":"10.1155\/2019\/2472754","article-title":"Intestinal permeability measured by urinary sucrose excretion correlates with serum zonulin and faecal calprotectin concentrations in UC patients in remission","volume":"2019","author":"Wegh","year":"2019","journal-title":"J. Nutr. Metab."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1093\/jamia\/ocab165","article-title":"Computational drug repositioning of atorvastatin for ulcerative colitis","volume":"28","author":"Bai","year":"2021","journal-title":"J. Am. Med. Inform. Assoc."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1186\/s10020-024-01025-0","article-title":"The pleiotropic effects of statins: A comprehensive exploration of neurovascular unit modulation and blood\u2013brain barrier protection","volume":"30","author":"Liu","year":"2024","journal-title":"Mol. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1124\/jpet.102.044099","article-title":"The 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor pravastatin reduces disease activity and inflammation in dextran-sulfate induced colitis","volume":"305","author":"Sasaki","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"4559","DOI":"10.3748\/wjg.v23.i25.4559","article-title":"Anti-inflammatory and anti-apoptotic effects of rosuvastatin by regulation of oxidative stress in a dextran sulfate sodium-induced colitis model","volume":"23","author":"Shin","year":"2017","journal-title":"World J. Gastroenterol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"667","DOI":"10.3109\/08923973.2011.559475","article-title":"The effect of atorvastatin and its role on systemic cytokine network in treatment of acute experimental colitis","volume":"33","author":"Aktunc","year":"2011","journal-title":"Immunopharmacol. Immunotoxicol."},{"key":"ref_22","first-page":"401","article-title":"Effect of Atorvastatin, a HMG-CoA Reductase Inhibitor, in Experimental Colitis in Mice","volume":"38","author":"Park","year":"2004","journal-title":"J. Pathol. Transl. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s10787-016-0263-6","article-title":"Atorvastatin attenuates TNBS-induced rat colitis: The involvement of the TLR4\/NF-kB signaling pathway","volume":"24","author":"Rashidian","year":"2016","journal-title":"Inflammopharmacology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/imm.12662","article-title":"Atorvastatin promotes the expansion of myeloid-derived suppressor cells and attenuates murine colitis","volume":"149","author":"Lei","year":"2016","journal-title":"Immunology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.intimp.2006.10.013","article-title":"Simvastatin inhibits NF-\u03baB signaling in intestinal epithelial cells and ameliorates acute murine colitis","volume":"7","author":"Lee","year":"2007","journal-title":"Int. Immunopharmacol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/fcp.12563","article-title":"Targeting IL-10, ZO-1 gene expression and IL-6\/STAT-3 trans-signaling by a combination of atorvastatin and mesalazine to enhance anti-inflammatory effects and attenuates progression of oxazolone-induced colitis","volume":"35","year":"2021","journal-title":"Fundam. Clin. Pharmacol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.1007\/s10787-024-01560-6","article-title":"Pentoxifylline in patients with ulcerative colitis treated with mesalamine by modulation of IL-6\/STAT3, ZO-1, and S1P pathways: A randomized controlled double-blinded study","volume":"32","author":"Bahaa","year":"2024","journal-title":"Inflammopharmacology"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"112541","DOI":"10.1016\/j.intimp.2024.112541","article-title":"Repurposing metformin as adjuvant therapy in patients with ulcerative colitis treated with mesalamine: A randomized controlled double-blinded study","volume":"138","author":"Hegazy","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Binsaleh, A.Y., El-Haggar, S.M., Hegazy, S.K., Maher, M.M., Bahgat, M.M., Elmasry, T.A., Alrubia, S., Alsegiani, A.S., Eldesoqui, M., and Bahaa, M.M. (2025). The adjunctive role of metformin in patients with mild to moderate ulcerative colitis: A randomized controlled study. Front. Pharmacol., 16.","DOI":"10.3389\/fphar.2025.1507009"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Alarfaj, S.J., El-Haggar, S.M., Hegazy, S.K., Maher, M.M., Bahgat, M.M., Elmasry, T.A., Alrubia, S., Alsegiani, A.S., and Bahaa, M.M. (2025). Effect of a high dose atorvastatin as adjuvant therapy to mesalamine in attenuating inflammation and symptoms in patients with ulcerative colitis: A randomized controlled pilot study. Front. Med., 11.","DOI":"10.3389\/fmed.2024.1490178"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.jclinepi.2011.07.011","article-title":"The size of a pilot study for a clinical trial should be calculated in relation to considerations of precision and efficiency","volume":"65","author":"Sim","year":"2012","journal-title":"J. Clin. Epidemiol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1111\/apt.14688","article-title":"Systematic review: Safety of mesalazine in ulcerative colitis","volume":"47","author":"Sehgal","year":"2018","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0002-9343(97)00254-4","article-title":"Efficacy of metformin in type II diabetes: Results of a double-blind, placebo-controlled, dose-response trial","volume":"103","author":"Garber","year":"1997","journal-title":"Am. J. Med."},{"key":"ref_34","first-page":"971","article-title":"An index of disease activity in patients with ulcerative colitis","volume":"87","author":"Seo","year":"1992","journal-title":"Am. J. Gastroenterol. (Springer Nat.)"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S2468-1253(23)00313-8","article-title":"Acute severe ulcerative colitis management: Unanswered questions and latest insights","volume":"9","author":"Suen","year":"2024","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"122790","DOI":"10.1016\/j.lfs.2024.122790","article-title":"Atorvastatin improved ulcerative colitis in association with gut microbiota-derived tryptophan metabolism","volume":"351","author":"Gou","year":"2024","journal-title":"Life Sci."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13321-020-00450-7","article-title":"A review of computational drug repositioning: Strategies, approaches, opportunities, challenges, and directions","volume":"12","author":"Jarada","year":"2020","journal-title":"J. Cheminform."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: Progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Aldossary, K.M., Ali, L.S., Abdallah, M.S., Bahaa, M.M., Elmasry, T.A., Elberri, E.I., Kotkata, F.A., El Sabaa, R.M., Elmorsi, Y.M., and Kamel, M.M. (2024). Effect of a high dose atorvastatin as added-on therapy on symptoms and serum AMPK\/NLRP3 inflammasome and IL-6\/STAT3 axes in patients with major depressive disorder: Randomized controlled clinical study. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1381523"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"5239","DOI":"10.2147\/DDDT.S490772","article-title":"Fenofibrate as an Adjunct Therapy for Ulcerative Colitis: Targeting Inflammation via SIRT1, NLRP3, and AMPK Pathways: A Randomized Controlled Pilot Study","volume":"18","author":"Alarfaj","year":"2024","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_41","first-page":"7607","article-title":"A randomized placebo-controlled, double-blind study to investigate the effect of a high oral loading dose of cholecalciferol in non-alcoholic fatty liver disease patients, new insights on serum STAT-3 and hepassocin","volume":"27","author":"Alarfaj","year":"2023","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"El-Haggar, S.M., Hegazy, S.K., Abd-Elsalam, S.M., and Bahaa, M.M. (2022). Pentoxifylline, a nonselective phosphodiesterase inhibitor, in adjunctive therapy in patients with irritable bowel syndrome treated with mebeverine. Biomed. Pharmacother., 145.","DOI":"10.1016\/j.biopha.2021.112399"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/jcpt.13556","article-title":"Open-label pilot study of ethosuximide as adjunctive therapy for relieving abdominal pain related to irritable bowel syndrome","volume":"47","author":"Hegazy","year":"2022","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_44","first-page":"3132","article-title":"Nitazoxanide-based therapeutic regimen as a novel treatment for Helicobacter pylori infection in children and adolescents: A randomized trial","volume":"26","author":"Shawky","year":"2022","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/fcp.12859","article-title":"Therapeutic effects and the impact of statins in the prevention of ulcerative colitis in preclinical models: A systematic review","volume":"37","author":"Vital","year":"2023","journal-title":"Fundam. Clin. Pharmacol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s00011-007-6177-4","article-title":"Disease modifying effect of statins in dextran sulfate sodium model of mouse colitis","volume":"57","author":"Kanagarajan","year":"2008","journal-title":"Inflamm. Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s12664-013-0420-4","article-title":"Randomized clinical trial: Atorvastatin versus placebo in patients with acute exacerbation of mild to moderate ulcerative colitis","volume":"33","author":"Dhamija","year":"2014","journal-title":"Indian J. Gastroenterol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1016\/j.jacc.2013.08.1627","article-title":"High-dose atorvastatin reduces periodontal inflammation: A novel pleiotropic effect of statins","volume":"62","author":"Subramanian","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.amjcard.2008.03.057","article-title":"Comparison effect of atorvastatin (10 versus 80 mg) on biomarkers of inflammation and oxidative stress in subjects with metabolic syndrome","volume":"102","author":"Singh","year":"2008","journal-title":"Am. J. Cardiol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1038\/bjp.2008.369","article-title":"Use of atorvastatin as an anti-inflammatory treatment in Crohn\u2019s disease","volume":"155","author":"Grip","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1089\/jmf.2012.2672","article-title":"Comparative protective effect of hawthorn berry hydroalcoholic extract, atorvastatin, and mesalamine on experimentally induced colitis in rats","volume":"16","author":"Malekinejad","year":"2013","journal-title":"J. Med. Food"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1002\/ibd.21822","article-title":"Statins are associated with reduced use of steroids in inflammatory bowel disease: A retrospective cohort study","volume":"18","author":"Crockett","year":"2012","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1016\/j.freeradbiomed.2003.09.016","article-title":"Increased disease activity in eNOS-deficient mice in experimental colitis","volume":"35","author":"Sasaki","year":"2003","journal-title":"Free Radic. Biol. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"17","DOI":"10.4103\/0253-7613.150311","article-title":"Protective effect of simvastatin and rosuvastatin on trinitrobenzene sulfonic acid-induced colitis in rats","volume":"47","author":"Maheshwari","year":"2015","journal-title":"Indian J. Pharmacol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1189\/jlb.1204697","article-title":"Myeloperoxidase: Friend and foe","volume":"77","author":"Klebanoff","year":"2005","journal-title":"J. Leukoc. Biol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1007\/s10620-012-2027-5","article-title":"Evaluation of fecal myeloperoxidase as a biomarker of disease activity and severity in ulcerative colitis","volume":"57","author":"Masoodi","year":"2012","journal-title":"Dig. Dis. Sci."},{"key":"ref_57","first-page":"e1004","article-title":"Fecal myeloperoxidase as a biomarker for inflammatory bowel disease","volume":"9","author":"Hansberry","year":"2017","journal-title":"Cureus"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ejphar.2011.04.030","article-title":"The effect of pentoxifylline and its metabolite-1 on inflammation and fibrosis in the TNBS model of colitis","volume":"662","author":"Peterson","year":"2011","journal-title":"Eur. J. Pharmacol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s10620-009-0780-x","article-title":"Preventive effect of pentoxifylline on acute radiation damage via antioxidant and anti-inflammatory pathways","volume":"55","author":"Akguner","year":"2010","journal-title":"Dig. Dis. Sci."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1097\/FJC.0000000000000731","article-title":"Cardioprotective effects of atorvastatin are mediated through PPAR\u03b3 in paraquat-exposed rats","volume":"74","author":"Malekinejad","year":"2019","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.etap.2016.11.011","article-title":"Atorvastatin protected from paraquat-induced cytotoxicity in alveolar macrophages via down-regulation of TLR-4","volume":"49","author":"Malekinejad","year":"2017","journal-title":"Environ. Toxicol. Pharmacol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"95","DOI":"10.23736\/S0026-4806.18.05787-7","article-title":"Serum zonulin in patients with inflammatory bowel disease: A pilot study","volume":"110","author":"Caviglia","year":"2019","journal-title":"Minerva Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1080\/08923973.2021.1878214","article-title":"Metformin alleviates inflammation in oxazolone induced ulcerative colitis in rats: Plausible role of sphingosine kinase 1\/sphingosine 1 phosphate signaling pathway","volume":"43","year":"2021","journal-title":"Immunopharmacol. Immunotoxicol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"69","DOI":"10.12688\/f1000research.20510.1","article-title":"All disease begins in the (leaky) gut: Role of zonulin-mediated gut permeability in the pathogenesis of some chronic inflammatory diseases","volume":"9","author":"Fasano","year":"2020","journal-title":"F1000Research"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e1251384","DOI":"10.1080\/21688370.2016.1251384","article-title":"Zonulin, a regulator of epithelial and endothelial barrier functions, and its involvement in chronic inflammatory diseases","volume":"4","author":"Sturgeon","year":"2016","journal-title":"Tissue Barriers"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/jcp.26064","article-title":"Statin regulated ERK5 stimulates tight junction formation and reduces permeability in human cardiac endothelial cells","volume":"233","author":"Wilkinson","year":"2018","journal-title":"J. Cell. Physiol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/j.yexcr.2012.05.009","article-title":"Atorvastatin preserves the integrity of endothelial adherens junctions by inhibiting vascular endothelial cadherin tyrosine phosphorylation","volume":"318","author":"Haidari","year":"2012","journal-title":"Exp. Cell Res."},{"key":"ref_68","first-page":"893","article-title":"The role of mesalamine in the treatment of ulcerative colitis","volume":"3","author":"Karagozian","year":"2007","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1084\/jem.20041948","article-title":"Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-\u03b3","volume":"201","author":"Rousseaux","year":"2005","journal-title":"J. Exp. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1080\/00365510701452838","article-title":"Fecal levels of leukocyte markers reflect disease activity in patients with ulcerative colitis","volume":"67","author":"Peterson","year":"2007","journal-title":"Scand. J. Clin. Lab. Investig."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1111\/j.1440-1746.2009.06048.x","article-title":"Fecal lactoferrin, myeloperoxidase and serum C-reactive are effective biomarkers in the assessment of disease activity and severity in patients with idiopathic ulcerative colitis","volume":"24","author":"Masoodi","year":"2009","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1093\/ecco-jcc\/jjac098","article-title":"Faecal myeloperoxidase as a biomarker of endoscopic activity in inflammatory bowel disease","volume":"16","author":"Swaminathan","year":"2022","journal-title":"J. Crohn\u2019s Colitis"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/9\/3077\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:24:08Z","timestamp":1760030648000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/9\/3077"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,29]]},"references-count":72,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["jcm14093077"],"URL":"https:\/\/doi.org\/10.3390\/jcm14093077","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,29]]}}}